The Role of SGLT2i in Management of Moderate AS
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.
Also called NCT06469645
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 2/3
- Enrolled
- 104 participants
- Sponsor
- Registry
-
NCT06469645
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06469645. Randomized; no masking; primary purpose prevention. Start 2024-05-30 (actual); primary completion 2026-07-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Role of SGLT2i in Management of Moderate AS
- Condition
- Moderate Aortic Valve Stenosis
- Intervention (Drug)
- Empagliflozin 10 MG
- Lead sponsor
- University of East Anglia
- Collaborator
- Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)
Record details
- Record id
cardio:ct-nct06469645- Content hash
b4a11e73389362072425d4955fdec6a131b50ce20393801aa7157c7992ab8269